March 24, 2018 3:09 AM ET

Healthcare Equipment and Supplies

Company Overview of Randox Laboratories Limited

Company Overview

Randox Laboratories Limited researches, designs, develops, manufactures, markets, and exports healthcare diagnostic products. The company offers biochip analyzers, immunoassays, and molecular diagnostics; clinical chemistry analyzers; diagnostic reagents; and multi-analyte liquid tumor marker controls. It also provides RIQAS, an external quality assessment scheme; and contract manufacturing services. In addition, the company offers Randox Molecular that provides a range of molecular arrays and assay formats to offer diagnostic, prognostic, and predictive solutions for infectious diseases, cardiovascular diseases, and cancer. It serves hospital laboratories, forensic laboratories, A&E units, ...

55 Diamond Road

Crumlin,  BT29 4QY

United Kingdom

Founded in 1982


44 2894 422 413


44 2894 452 912

Key Executives for Randox Laboratories Limited

Owner and Managing Director
Randox US QC Sales Director
Compensation as of Fiscal Year 2017.

Randox Laboratories Limited Key Developments

Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors

Transgene and Randox entered into a collaboration to combine their technologies and develop multifunctional oncolytic immunotherapies. Innovative oncolytic viruses (OVs) resulting from this collaboration will use Transgene's proprietary viral platform Invir.IOTM in which one or more of Randox’s SdAbs (single-domain antibodies) will be vectorized. The immunotherapies resulting from this collaboration will combine the oncolytic effect of the viruses with the properties of the vectorized SdAbs that will be locally expressed in the tumor microenvironment (TME) with the aim of treating immunosuppressed solid tumors. Under the terms of the agreement, Transgene will develop novel anticancer oncolytic virus drugs using its proprietary Vaccinia virus (TK-, RR-) strain, and its expertise in molecular engineering and translational research. This novel viral strain offers increased oncolytic properties. In addition, its large genome capacity, which is very differentiating, enables multiple therapeutic payloads to be delivered in the tumor, where the virus replicates. Randox will provide expertise in antibody engineering and make available its collection of new and future immunotherapeutic SdAbs to be used as vectorized payloads. These SdAbs have the potential to modulate the patient’s immune response and produce a powerful synergistic effect with Transgene’s oncolytic viral platform. Transgene’s Invir.IOTM technology is an efficient way to target immunosuppressive pathways directly in the tumor microenvironment. By locally expressing one or several SdAbs in the TME, the viral-based approach promises to optimize the efficacy of the encoded therapeutic agents, while reducing their associated side effects, often reported after systemic administration. Novel OV products generated from the collaboration have the potential to be significantly more effective than a combination of single agents. Transgene previously reported a preclinical proof-of-concept data showing that an oncolytic Vaccinia virus encoding a sequence of anti-PD1 demonstrated better overall survival than the combination of separate single agents.

Randox Laboratories Limited Presents at Sachs Associates 10th Annual European Life Sciences CEO Forum & Exhibition, Mar-06-2017 05:00 PM

Randox Laboratories Limited Presents at Sachs Associates 10th Annual European Life Sciences CEO Forum & Exhibition, Mar-06-2017 05:00 PM. Venue: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Switzerland. Speakers: Claire Huguet, Head of Biomarker Services.

Randox Laboratories Wins Multiple Awardees Contract for Supplying Microbiology, Serology, Virology, Immunology Equipment, Consumables and Reagents

NORMANTON, United Kingdom, May 18 -- Randox Holdings Ltd. TA Randox Laboratories Ltd. UKN won a multiple awardees contract award from NHS Supply Chain acting as agent for NHS Business Services Authority for the supply of Randox Laboratories Ltd. won a multiple awardees contract award from NHS Supply Chain acting as agent for NHS Business Services Authority for the supply of microbiology, serology, virology and immunology equipment, consumables and reagents.

Similar Private Companies By Industry

Company Name Region
11 Health Limited Europe
3D LifePrints UK Ltd Europe
A. Algeo Limited Europe
Abingdon Health Ltd. Europe
Accentus Medical Ltd. Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Randox Laboratories Limited, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at